SHOP
SHOP

Science

BioVinc has demonstrated its product OsteoFloxacin™ is the only antibiotic known to kill the deadly methicillin-resistant Staphylococcus aureus (MRSA) within mature bone biofilms.

First-in-Class PJI Medicine

OsteoFloxacin™ is designed to address the unmet medical need of prosthetic joint infections (PJI). Preclinical studies demonstrate its ability to eradicate all bacterial biofilms associated with PJI, including those deeply embedded in bone, offering a true cure for patients.

Explore how OsteoFloxacin™’s unique targeting and benefits surpass the standard of care for PJI — delivering complete infection eradication and reducing the risk of amputation or mortality*.

*This animation is based on published in vitro/in vivo data and conceptual information for our product and does not represent actual results in human studies.

Disease Targeting

OsteoFloxacin™ revolutionizes the treatment of skeletal infections, thanks to its unique bone mineral-binding property. Unlike any other treatment approach, it focuses on diseased infection sites without affecting the entire skeleton. It precisely targets these sites, where bone mineral is most exposed. Furthermore, OsteoFloxacin™ delivers maximum efficacy while clearing quickly from the bloodstream to minimize side effects.

view data

Sustained Efficacy

OsteoFloxacin™ delivers a true, long-term cure for skeletal infections, surpassing the temporary relief offered by the standard of care (SOC). Unlike SOC treatments, OsteoFloxacin™ eradicates all bacteria, including those hidden deep within the osteocyte lacunar canalicular network (OLCN)—an area with no blood flow and a key source of recurrence.

BioVinc Platform Technology

Leading the way in bone-selective drug discovery and development, BioVinc delivers superior effectiveness and safety.

  • Innovative Platform: Designs skeletal-selective drug conjugates to target bone infections and related diseases.
  • Primary Focus: Tackling prosthetic joint infections with precision.
  • Reduced Development Risk: Leverages proven drug classes as conjugate components for greater reliability.

Key Publications

  1. Wang, Hannah; Lekkala, Sashank; Ren, Youliang; Tay, Allie Jia Hui; Neighbors, Jeffrey; Ebetino, Frank H; Sun, Shuting; Joseph, Noah M; Schwarz, Edward M; Xie, Chao. Effects of Hydroxybisphosphonates-Conjugated Sitafloxacin on Fracture Healing and Skeletal Growth in Mice. JBMR Plus. 2026, 10(2):1.
  2. Vanvelk, Niels; Tapia-Dean, James; Zeiter, Stephan; de Mesy Bentley, Karen; Xie, Chao; Ebetino, Frank Hal; Sun, Shuting; Neighbors, Jeffrey; Schwarz, Edward M; Moriarty, Thomas Fintan. Bisphosphonate-Conjugated Sitafloxacin for the Treatment of Staphylococcus aureus Infection Associated with Cortical Bone Screws: Case Series in Sheep Model. Pharmaceuticals. 2025; 18(5):675.
  3. Ren Y, Weeks J, Xue T, Rainbolt J, de Mesy Bentley KL, Shu Y, et al. Evidence of bisphosphonate-conjugated sitafloxacin eradication of established methicillin-resistant S. aureus infection with osseointegration in murine models of implant-associated osteomyelitis. Bone Res. 2023;11(1):51.
  4. Ren Y, Xue T, Rainbolt J, Bentley KLM, Galloway CA, Liu Y, et al. Efficacy of Bisphosphonate-Conjugated Sitafloxacin in a Murine Model of S. aureus Osteomyelitis: Evidence of “Target & Release” Kinetics and Killing of Bacteria Within Canaliculi. Front Cell Infect Microbiol. 2022;12:910970.
  5. Ebetino FH, Sun S, Cherian P, Roshandel S, Neighbors JD, Hu E, et al. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use. Bone. 2022;156:116289.
  6. Sun S, Tao J, Sedghizadeh PP, Cherian P, Junka AF, Sodagar E, et al. Bisphosphonates for delivering drugs to bone. Br J Pharmacol. 2021;178(9):2008-25.
  7. Adjei-Sowah E, Peng Y, Weeks J, Jonason JH, de Mesy Bentley KL, Masters E, et al. Development of Bisphosphonate-Conjugated Antibiotics to Overcome Pharmacodynamic Limitations of Local Therapy: Initial Results with Carbamate Linked Sitafloxacin and Tedizolid. Antibiotics (Basel). 2021;10(6).
  8. Xing, L, Ebetino, FH, Boeckman Jr, RK, Srinivasan, V, Tao, J, Sawyer, TK, Li, J, Yao, Z, Boyce, BF. Targeting anti-cancer agents to bone using bisphosphonates. Bone 2020; 138:115492. PMID: 32585321
  9. Sedghizadeh PP, Sun S, Junka AF, Richard E, Sadrerafi K, Mahabady S, et al. Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. J Med Chem. 2017;60(6):2326-43.